

February 14, 2024

Dear Valued Partner,

At Johnson & Johnson MedTech Vision, our mission is to help every person see their world clearly. Every year, we improve and preserve sight for more than 40 million people around the world, and we see the opportunity to reach even more.

We are reaching out to make you aware that we are discontinuing the ACUVUE® Theravision® with Ketotifen product line globally. In Canada, we will discontinue the product on **December 28<sup>th</sup> 2024**. During this period, you will be able to only purchase existing inventory.


New or existing patients currently wearing ACUVUE® Theravision® with Ketotifen and looking for premium daily disposable options, could be recommended **ACUVUE® OASYS 1-Day** for outstanding performance, including comfort powered by tears<sup>\*,1</sup>, or **ACUVUE® OASYS MAX 1-Day** with the extra benefits of ~60% blue-violet light filtering<sup>+,2</sup> and reduced tear film evaporation<sup>3</sup> or **1-DAY ACUVUE® MOIST** for proven daily disposable performance and unbeaten comfort<sup>+,+</sup>. For patients who wish to stay in reusable lenses, they should be recommended **ACUVUE® OASYS 2-Week**. In 29 clinical studies posted on ClinicalTrials.gov, the ACUVUE® OASYS Brand family has never been beaten in comfort<sup>‡</sup>.

You can return any ACUVUE® Theravision® with Ketotifen product on hand up to 6 months after the discontinuation date.

As a company with a strong legacy of first-to-market innovation, we are so proud of this first-in-class innovation. We remain committed to researching and developing new technologies and innovations that can correct, enhance, and restore vision for patients today and in the long-term.

Should you have questions regarding this notice, please contact Customer Service at 1-800-267-5098 or speak with your Sales Representative.

On behalf of the Vision team at Johnson & Johnson MedTech, **thank you** for your continued support of the ACUVUE® Brand.



Marcus Savoio  
General Manager  
Johnson & Johnson Vision Care, a division of Johnson & Johnson (Canada) Inc.

Johnson & Johnson

\*Designed to support the functions of the tear film

<sup>‡</sup>29 clinical studies posted on ClinicalTrials.gov, a website maintained by the NIH, evaluated subjective comfort as primary or secondary endpoint for ACUVUE® OASYS Brand 2-week family and daily disposable contact lens families vs. competitors' products as of October 31, 2023.

<sup>+</sup>Filtering of HEV light by contact lenses has not been demonstrated to confer any health benefit to the user, including but not limited to retinal protection, protection from cataract progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information.

<sup>+,+</sup>14 clinical studies posted on ClinicalTrials.gov, a website maintained by the NIH, evaluated subjective comfort as a primary or secondary endpoint for 1-DAY ACUVUE® MOIST Brand family (spherical, astigmatism, and multifocal) contact lenses vs. competitors' products as of April 30, 2023.

**1.** JJV Data on File 2021. HydraLuxe® Technology Definition. **2.** JJV Data on File 2022. TearStable™ Technology Definition. **3.** JJV Data on File, 2022. CSM Subjective Responses ACUVUE® OASYS MAX 1-Day Contact Lenses- Retrospective Meta-analysis.

**Important safety information:** ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, a division of Johnson & Johnson (Canada) Inc., by calling 1-800-267-5098 or by visiting [jnvisionpro.ca](http://jnvisionpro.ca).

© Johnson & Johnson Vision Care, a division of Johnson & Johnson (Canada) Inc. 2024

200 Whitehall Drive, Markham, ON L3R 0T5